Original Literature | Model OverView |
---|---|
Publication
Title
Regulation of mitochondrial antiviral signaling pathways.
Affiliation
Department of Microbiology and Immunology, Lineberger Comprehensive CancerCenter, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599,USA. cbmoore2@med.unc.edu
Abstract
Mitochondrial antiviral immunity involves the detection of viral RNA byintracellular pattern-recognition receptors (PRRs) belonging to the RIG-I-likehelicase family. The convergence of these and other signaling molecules to theouter mitochondrial membrane results in the rapid induction of antiviralcytokines including type-1 interferon. Here, we discuss recent studiesdescribing new molecules implicated in the regulation of this antiviralresponse.
PMID
18549796
|
Entity
NF-kappaB
--
MO000000058
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m30
10
infinite
0
TRANSPATH | MO000000058 |
--
protein remnants
--
MO000019479
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m360980
10
infinite
0
TRANSPATH | MO000019479 |
--
dsRNA
--
MO000022224
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m119368
10
infinite
0
TRANSPATH | MO000022224 |
--
IRF-3{p}
--
MO000041456
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m19324
10
infinite
0
TRANSPATH | MO000041456 |
--
DDX58
--
MO000066987
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m41844
10
infinite
0
TRANSPATH | MO000066987 |
--
MAVS
--
MO000094908
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m68199
10
infinite
0
TRANSPATH | MO000094908 |
--
RNF125
--
MO000107907
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m80707
10
infinite
0
TRANSPATH | MO000107907 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
IFN-alpha
--
e11
cso30:c:mRNA
cso30:i:CC_Cytosol
--
csml-variable:Double
m11
0
infinite
0
--
IFN-beta
--
e12
cso30:c:mRNA
cso30:i:CC_Cytosol
--
csml-variable:Double
m12
0
infinite
0
--
dsRNA:IFIH1:MAVS
--
e13
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m13
0
infinite
0
--
dsRNA:Ddx58:MAVS
--
e14
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m14
0
infinite
0
--
--
e15
cso30:c:EntityBiologicalCompartment
cso30:i:CC_MitochondrialChromosome
--
--
--
csml-variable:Double
m15
0
infinite
0
--
--
e16
cso30:c:EntityBiologicalCompartment
cso30:i:CC_MitochondrialCentromere
--
--
--
csml-variable:Double
m16
0
infinite
0
--
--
e17
cso30:c:EntityBiologicalCompartment
cso30:i:CC_MitochondrialMatrix
--
--
--
csml-variable:Double
m17
0
infinite
0
--
--
e18
cso30:c:EntityBiologicalCompartment
cso30:i:CC_MitochondrialIntermembraneSpace
--
--
--
csml-variable:Double
m18
0
infinite
0
--
--
e19
cso30:c:EntityBiologicalCompartment
cso30:i:CC_MitochondrialOuterMembrane
--
--
--
csml-variable:Double
m19
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
--
e20
cso30:c:EntityBiologicalCompartment
cso30:i:CC_MitochondrialEnvelope
--
--
--
csml-variable:Double
m20
0
infinite
0
--
--
e21
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Mitochondria
--
--
--
csml-variable:Double
m21
0
infinite
0
--
--
e22
cso30:c:EntityBiologicalCompartment
cso30:i:CC_MitochondrialInnerMembrane
--
--
--
csml-variable:Double
m22
0
infinite
0
--
--
e23
cso30:c:EntityBiologicalCompartment
cso30:i:CC_MitochondrialLumen
--
--
--
csml-variable:Double
m23
0
infinite
0
--
dsRNA:ddx58:MAVS:TRAF3
--
e24
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m24
0
infinite
0
--
type I interferon
--
e25
cso30:c:mRNA
cso30:i:CC_Cytosol
--
csml-variable:Double
m25
0
infinite
0
--
dsRNA:DDX58:MAVS:TRAF6
--
e26
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m26
0
infinite
0
--
NF-kappaB:IkappaB-alpha{p}
--
e28
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m28
0
infinite
0
--
NF-kappaB:IkappaB-alpha
--
e29
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m29
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
dsRNA:ddx58:MAVS:TRAF3{ub}:TANK:TBK1:IKK-i
--
e31
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m32
0
infinite
0
--
dsRNA:ddx58:MAVS:TRAF3{ub}:TANK:TBK1{active}:IKK-i{active}
--
e32
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m33
0
infinite
0
--
(IRF-3{p})2
--
e33
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m34
0
infinite
0
--
(IRF-3{p})2
--
e34
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m35
0
infinite
0
--
(IRF-7{p})2
--
e35
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m36
0
infinite
0
--
(IRF-7{p})2
--
e36
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m37
0
infinite
0
--
enhancesome complex:IFN-alpha
--
e37
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m38
0
infinite
0
--
csml-variable:Double
m39
0
infinite
0
--
csml-variable:Double
m40
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
enhancesome complex:IFN-beta
--
e40
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m41
0
infinite
0
--
type I interferon
--
e41
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m42
0
infinite
0
--
LGP2
--
e42
cso30:c:mRNA
cso30:i:CC_Cytosol
--
csml-variable:Double
m43
0
infinite
0
--
IFN-beta
--
e43
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m44
0
infinite
0
--
LGP2
--
e44
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m45
0
infinite
0
--
dsRNA:LGP2
--
e45
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m46
0
infinite
0
--
dsRNA:LGP2:MAVS
--
e46
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m47
0
infinite
0
--
csml-variable:Double
m48
0
infinite
0
--
IFIH1{ub}n:dsRNA
--
e48
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m49
0
infinite
0
--
RIG-I{ub}n:dsRNA
--
e49
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m63
0
infinite
0
--
dsRNA:IFIH1
--
e5
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m5
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
dsRNA:DDX58
--
e6
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m6
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
IRF-3{p}:PIN1
--
e63
cso30:c:Complex
cso30:i:CC_Extracellular
--
csml-variable:Double
m64
0
infinite
0
--
TRIM25
--
e64
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m65
0
infinite
0
--
dsRNA:ddx58:MAVS:TRAF3{ub}
--
e65
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m66
0
infinite
0
--
DUBA
--
e66
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m67
0
infinite
0
--
ddx58:MAVS:TRAF3{ub}:TANK:IKK-i
--
e67
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m68
0
infinite
0
--
Atg5-Atg12
--
e68
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m69
0
infinite
0
--
Atg5-Atg12:MAVS
--
e69
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m70
0
infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
IFIH1:Atg12:Atg5
--
e70
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m71
0
infinite
0
--
Atg5-Atg12:DDX58
--
e71
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m72
0
infinite
0
--
NLRX1
--
e72
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m73
0
infinite
0
--
MAVS:NLRX1
--
e73
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m74
0
infinite
0
--
ROS
--
e74
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m75
0
infinite
0
--
V protein
--
e75
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m76
0
infinite
0
--
ddx58:V protein
--
e76
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m77
0
infinite
0
--
3ABC
--
e77
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m78
0
infinite
0
--
NS3/4A
--
e78
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m79
0
infinite
0
--
NS3/4A:MAVS
--
e79
cso30:c:Complex
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m80
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
NS1
--
e80
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m81
0
infinite
0
--
NS1:DDX58
--
e81
cso30:c:Complex
cso30:i:CC_Extracellular
--
csml-variable:Double
m82
0
infinite
0
--
MAVS:NS1
--
e82
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m83
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
stoichiometry:c3 : 1
m76904*m119368*0.1
nodelay
--
0
PMID: 18549796 The ligands for RIG-I and MDA-5 are viral ¡Ènonself¡É nucleic acids, and like TLR signaling, a classical ligand-receptor-adaptor model of PRR signaling has been proposed for RLH-mediated signaling, culminating in the induction of antiviral type-1 interferon cytokines, such as IFN-¦Â and IFN-¦Á.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c25 : 1
stoichiometry:c119 : 1
stoichiometry:c24 : 1
m24*0.1
nodelay
--
0
PMID: 18549796, 18272355 The MAVS proline-rich domain contains a TRAF3-binding site required for association with TRAF3 and essential for MAVS-mediated activation of type-1 interferon, but not NF-¦ÊB. PMID: 18549796 The deubiquitinizing enzyme A (DUBA) cleaves Lys-63-linked polyubiquitin chains from TRAF3 resulting in the dissociation of TRAF3 from TBK1, and such a dissociation effectively squelches RLH-mediated type-1 interferon production.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c26 : 1
stoichiometry:c27 : 1
stoichiometry:c28 : 1
m183*m14*0.1
nodelay
--
0
PMID: 18549796, 16153868 Conversely, mutation of a MAVS TRAF6-binding site showed marked reduction in MAVS-mediated NF-¦ÊB activity, suggesting that TRAF6 mediates MAVS activation of NF-¦ÊB.
p12
p12
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c29 : 1
stoichiometry:c31 : 1
stoichiometry:c30 : 1
m207*m26*0.1
nodelay
--
0
PMID: 18549796 MAVS signaling downstream of TRAF6 is thought to involve the activation of the canonical I¦ÊB kinase (IKK) complex consisting of IKK¦Ã(NEMO):IKK¦Á:IKK¦Â, resulting in the phosphorylation of the inhibitor of NF-¦ÊB (I¦ÊB¦Á) and its subsequent release for translocation into the nucleus.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c32 : 1
stoichiometry:c34 : 1
stoichiometry:c33 : 1
m29*m27*0.1
nodelay
--
0
PMID: 18549796 MAVS signaling downstream of TRAF6 is thought to involve the activation of the canonical I¦ÊB kinase (IKK) complex consisting of IKK¦Ã(NEMO):IKK¦Á:IKK¦Â, resulting in the phosphorylation of the inhibitor of NF-¦ÊB (I¦ÊB¦Á) and its subsequent release for translocation into the nucleus.
p14
p14
cso30:i:ME_UnknownDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c35 : 1
stoichiometry:c38 : 1
stoichiometry:c39 : 1
m28*0.1
nodelay
--
0
PMID: 18549796 MAVS signaling downstream of TRAF6 is thought to involve the activation of the canonical I¦ÊB kinase (IKK) complex consisting of IKK¦Ã(NEMO):IKK¦Á:IKK¦Â, resulting in the phosphorylation of the inhibitor of NF-¦ÊB (I¦ÊB¦Á) and its subsequent release for translocation into the nucleus.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c36 : 1
stoichiometry:c37 : 1
m31*0.1
nodelay
--
0
PMID: 18549796 MAVS signaling downstream of TRAF6 is thought to involve the activation of the canonical I¦ÊB kinase (IKK) complex consisting of IKK¦Ã(NEMO):IKK¦Á:IKK¦Â, resulting in the phosphorylation of the inhibitor of NF-¦ÊB (I¦ÊB¦Á) and its subsequent release for translocation into the nucleus.
p16
p16
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c40 : 1
stoichiometry:c41 : 1
stoichiometry:c42 : 1
stoichiometry:c110 : 1
stoichiometry:c44 : 1
m3897*m3902*m1599*m66*0.1
nodelay
--
0
PMID: 18549796 In contrast, MAVS signaling downstream of TRAF3 involves the formation and activation of a different signaling complex consisting of MAVS, the TRAF-family-member-associated NF-¦ÊB activator (TANK), and a noncanonical class of IKKs including (TANK)-binding kinase 1 (TBK1) and inducible I¦ÊB kinase (IKK-? or IKK-var epsilon). PMID: 18549796 The deubiquitinizing enzyme A (DUBA) cleaves Lys-63-linked polyubiquitin chains from TRAF3 resulting in the dissociation of TRAF3 from TBK1, and such a dissociation effectively squelches RLH-mediated type-1 interferon production.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c45 : 1
stoichiometry:c46 : 1
m32*0.1
nodelay
--
0
PMID: 18549796 In contrast, MAVS signaling downstream of TRAF3 involves the formation and activation of a different signaling complex consisting of MAVS, the TRAF-family-member-associated NF-¦ÊB activator (TANK), and a noncanonical class of IKKs including (TANK)-binding kinase 1 (TBK1) and inducible I¦ÊB kinase (IKK-? or IKK-var epsilon).
p18
p18
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c47 : 1
stoichiometry:c49 : 1
stoichiometry:c156 : 1
stoichiometry:c157 : 1
stoichiometry:c48 : 1
m977*m33*0.1
nodelay
--
0
PMID: 18549796 The activation of TBK1 and IKK-? results in the phosphorylation and subsequent dimerization and nuclear translocation of the transcription factors IRF3 and IRF7. PMID: 18549796, 17079289 NS1 was found to complex with RIG-I and associate with MAVS at the mitochondria, thereby disrupting downstream activation of IRF-3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c50 : 1
stoichiometry:c51 : 1
m19324*0.1
nodelay
--
0
PMID: 18549796 The activation of TBK1 and IKK-? results in the phosphorylation and subsequent dimerization and nuclear translocation of the transcription factors IRF3 and IRF7.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c5 : 1
stoichiometry:c6 : 1
m119368*m48*0.1
nodelay
--
0
PMID: 18549796 The ligands for RIG-I and MDA-5 are viral ¡Ènonself¡É nucleic acids, and like TLR signaling, a classical ligand-receptor-adaptor model of PRR signaling has been proposed for RLH-mediated signaling, culminating in the induction of antiviral type-1 interferon cytokines, such as IFN-¦Â and IFN-¦Á.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c52 : 1
stoichiometry:c53 : 1
m34*0.1
nodelay
--
0
PMID: 18549796 The activation of TBK1 and IKK-? results in the phosphorylation and subsequent dimerization and nuclear translocation of the transcription factors IRF3 and IRF7.
p21
p21
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c54 : 1
stoichiometry:c56 : 1
stoichiometry:c55 : 1
m980*m33*0.1
nodelay
--
0
PMID: 18549796 The activation of TBK1 and IKK-? results in the phosphorylation and subsequent dimerization and nuclear translocation of the transcription factors IRF3 and IRF7.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c57 : 1
stoichiometry:c58 : 1
m19325*0.1
nodelay
--
0
PMID: 18549796 The activation of TBK1 and IKK-? results in the phosphorylation and subsequent dimerization and nuclear translocation of the transcription factors IRF3 and IRF7.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c59 : 1
stoichiometry:c60 : 1
m37*0.1
nodelay
--
0
PMID: 18549796 The activation of TBK1 and IKK-? results in the phosphorylation and subsequent dimerization and nuclear translocation of the transcription factors IRF3 and IRF7.
p24
p24
cso30:i:ME_DNABinding
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c61 : 1
stoichiometry:c62 : 1
stoichiometry:c63 : 1
stoichiometry:c65 : 1
stoichiometry:c64 : 1
m36*m35*m30*m39*0.1
nodelay
--
0
PMID: 18549796 Because it is known that both NF-¦ÊB and IRF3 and IRF7 are required for the assembly of an enhancesome complex required for the induction of IFN-¦Â and IFN-¦Á promoters, the essential role of MAVS in the activation of both of these transcription factors further emphasizes the importance of this mitochondrial adaptor protein in type-1 interferon signaling.
p25
p25
cso30:i:ME_DNABinding
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c66 : 1
stoichiometry:c68 : 1
stoichiometry:c69 : 1
stoichiometry:c70 : 1
stoichiometry:c67 : 1
m40*m35*m36*m30*0.1
nodelay
--
0
PMID: 18549796 Because it is known that both NF-¦ÊB and IRF3 and IRF7 are required for the assembly of an enhancesome complex required for the induction of IFN-¦Â and IFN-¦Á promoters, the essential role of MAVS in the activation of both of these transcription factors further emphasizes the importance of this mitochondrial adaptor protein in type-1 interferon signaling.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c71 : 1
stoichiometry:c73 : 1
stoichiometry:c72 : 1
m25*m24*0.1
nodelay
--
0
PMID: 18549796, 18272355 The MAVS proline-rich domain contains a TRAF3-binding site required for association with TRAF3 and essential for MAVS-mediated activation of type-1 interferon, but not NF-¦ÊB.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c75 : 1
stoichiometry:c74 : 1
m42*0.1
nodelay
--
0
PMID: 18549796 In fact, RIG-I-mediated production of IFN can, in turn, increase the transcription of RIG-I itself, thus setting into motion an IFN amplification loop, which if left unchecked, could become deleterious to the host.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c77 : 1
stoichiometry:c76 : 1
m44*0.1
nodelay
--
0
PMID: 18549796, 18262678 similar to RIG-I, LGP2 is inducible by IFN-¦Â, virus, or dsRNA and can bind viral RNA through a RIG-I-like C-terminal domain.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c78 : 1
stoichiometry:c80 : 1
stoichiometry:c79 : 1
m43*m44*0.1
nodelay
--
0
PMID: 18549796, 18262678 similar to RIG-I, LGP2 is inducible by IFN-¦Â, virus, or dsRNA and can bind viral RNA through a RIG-I-like C-terminal domain.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c8 : 1
stoichiometry:c9 : 1
m5*0.1
nodelay
--
0
PMID: 18549796 The ligands for RIG-I and MDA-5 are viral ¡Ènonself¡É nucleic acids, and like TLR signaling, a classical ligand-receptor-adaptor model of PRR signaling has been proposed for RLH-mediated signaling, culminating in the induction of antiviral type-1 interferon cytokines, such as IFN-¦Â and IFN-¦Á.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c81 : 1
stoichiometry:c82 : 1
stoichiometry:c83 : 1
m45*m119368*0.1
nodelay
--
0
PMID: 18549796, 18262678 similar to RIG-I, LGP2 is inducible by IFN-¦Â, virus, or dsRNA and can bind viral RNA through a RIG-I-like C-terminal domain.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c84 : 1
stoichiometry:c85 : 1
stoichiometry:c86 : 1
m46*m68199*0.1
nodelay
--
0
PMID: 18549796 Another intriguing property of LGP2 is its ability to associate with MAVS despite the loss of CARDs.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c87 : 1
stoichiometry:c89 : 1
stoichiometry:c88 : 1
m41844*0.1
nodelay
--
0
PMID: 18549796 LGP2 contains a RIG-I-like repression domain (RD) capable of inhibiting RIG-I multimerization and signaling.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c90 : 1
stoichiometry:c92 : 1
stoichiometry:c91 : 1
m5*m80707*0.1
nodelay
--
0
--
p34
p34
cso30:i:ME_ProteasomeDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c93 : 1
stoichiometry:c94 : 1
stoichiometry:c95 : 1
m49*0.1
nodelay
--
0
PMID: 18549796, 17460044 The IFN-inducible ubiquitin ligase RNF125 was found to conjugate lysine 48-linked polyubiquitin chains to RIG-I or MDA-5 and cause the proteosomal degradation of either protein.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c96 : 1
stoichiometry:c97 : 1
stoichiometry:c98 : 1
m6*m80707*0.1
nodelay
--
0
PMID: 18549796, 17460044 The IFN-inducible ubiquitin ligase RNF125 was found to conjugate lysine 48-linked polyubiquitin chains to RIG-I or MDA-5 and cause the proteosomal degradation of either protein.
p36
p36
cso30:i:ME_ProteasomeDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c99 : 1
stoichiometry:c100 : 1
m63*0.1
nodelay
--
0
PMID: 18549796, 17460044 The IFN-inducible ubiquitin ligase RNF125 was found to conjugate lysine 48-linked polyubiquitin chains to RIG-I or MDA-5 and cause the proteosomal degradation of either protein.
p37
p37
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c101 : 1
stoichiometry:c102 : 1
stoichiometry:c103 : 1
m19324*m2065*0.1
nodelay
--
0
PMID: 18549796, 16699525 Upon transfection with dsRNA, the peptidyl-prolyl isomerase (Pin1) interacts with phosphorylated IRF3, resulting in the proteasomal degradation of IRF3.
p38
p38
cso30:i:ME_ProteasomeDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c104 : 1
stoichiometry:c105 : 1
stoichiometry:c106 : 1
m64*0.1
nodelay
--
0
PMID: 18549796, 16699525 Upon transfection with dsRNA, the peptidyl-prolyl isomerase (Pin1) interacts with phosphorylated IRF3, resulting in the proteasomal degradation of IRF3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c107 : 1
stoichiometry:c109 : 1
stoichiometry:c108 : 1
m6*m65*0.1
nodelay
--
0
PMID: 18549796 TRIM25, functions as an E3 ubiquitin ligase of RIG-I. The SPRY domain of TRIM25 delivers a lysine 63-linked ubiquitin moiety to the N-terminal CARDs of RIG-I, which strengthens interactions with MAVS and enhances downstream signaling to IFN-¦Â.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c7 : 1
stoichiometry:c10 : 1
m6*0.1
nodelay
--
0
PMID: 18549796 The ligands for RIG-I and MDA-5 are viral ¡Ènonself¡É nucleic acids, and like TLR signaling, a classical ligand-receptor-adaptor model of PRR signaling has been proposed for RLH-mediated signaling, culminating in the induction of antiviral type-1 interferon cytokines, such as IFN-¦Â and IFN-¦Á.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c43 : 1
stoichiometry:c111 : 1
m24*0.1
nodelay
--
0
PMID: 18549796 The deubiquitinizing enzyme A (DUBA) cleaves Lys-63-linked polyubiquitin chains from TRAF3 resulting in the dissociation of TRAF3 from TBK1, and such a dissociation effectively squelches RLH-mediated type-1 interferon production.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c112 : 1
stoichiometry:c114 : 1
stoichiometry:c113 : 1
m66*m67*0.1
nodelay
--
0
PMID: 18549796 The deubiquitinizing enzyme A (DUBA) cleaves Lys-63-linked polyubiquitin chains from TRAF3 resulting in the dissociation of TRAF3 from TBK1, and such a dissociation effectively squelches RLH-mediated type-1 interferon production.
p42
p42
cso30:i:ME_Dissociation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c117 : 1
stoichiometry:c115 : 1
stoichiometry:c116 : 1
stoichiometry:c118 : 1
m24*m33*0.1
nodelay
--
0
PMID: 18549796 The deubiquitinizing enzyme A (DUBA) cleaves Lys-63-linked polyubiquitin chains from TRAF3 resulting in the dissociation of TRAF3 from TBK1, and such a dissociation effectively squelches RLH-mediated type-1 interferon production.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c120 : 1
stoichiometry:c121 : 1
stoichiometry:c122 : 1
m68199*m69*0.1
nodelay
--
0
PMID: 18549796 In the absence of viral infection, the Atg5-Atg12 conjugate interacts directly with the MAVS CARD and weakly associated with RIG-I and MDA-5 CARDs.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c123 : 1
stoichiometry:c124 : 1
stoichiometry:c125 : 1
m69*m76904*0.1
nodelay
--
0
PMID: 18549796 In the absence of viral infection, the Atg5-Atg12 conjugate interacts directly with the MAVS CARD and weakly associated with RIG-I and MDA-5 CARDs.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c126 : 1
stoichiometry:c127 : 1
stoichiometry:c128 : 1
m41844*m69*0.1
nodelay
--
0
PMID: 18549796 In the absence of viral infection, the Atg5-Atg12 conjugate interacts directly with the MAVS CARD and weakly associated with RIG-I and MDA-5 CARDs.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c129 : 1
stoichiometry:c130 : 1
stoichiometry:c131 : 1
m68199*m73*0.1
nodelay
--
0
PMID: 18549796 NLRX1 was found to interact with MAVS and block RIG-I-MAVS interactions and signaling after Sendai virus infection.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c134 : 1
stoichiometry:c133 : 1
m73*0.1
nodelay
--
0
PMID: 18549796, 18219313 Reactive oxygen species (ROS) production is increased with NLRX1 overexpression.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c135 : 1
stoichiometry:c136 : 1
stoichiometry:c137 : 1
m41844*m76*0.1
nodelay
--
0
PMID: 18549796, 18272355 Each of these RNA viruses encode for a V protein that binds to MDA-5 and inhibits dsRNA or MDA-5 induction of IFN-¦Â promoter activity.
p49
p49
cso30:i:ME_ProteinCleavage
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c138 : 1
stoichiometry:c140 : 1
stoichiometry:c139 : 1
m68199*m78*0.1
nodelay
--
0
PMID: 18549796, 17438296 This virus targets the RIG-I pathway downstream of RIG-I and upstream of the TBK1-IKK-var epsilon complex by cleaving MAVS utilizing a virally encoded protease, 3ABC.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c14 : 1
stoichiometry:c11 : 1
m5*0.1
nodelay
--
0
PMID: 18549796 The ligands for RIG-I and MDA-5 are viral ¡Ènonself¡É nucleic acids, and like TLR signaling, a classical ligand-receptor-adaptor model of PRR signaling has been proposed for RLH-mediated signaling, culminating in the induction of antiviral type-1 interferon cytokines, such as IFN-¦Â and IFN-¦Á.
p50
p50
cso30:i:ME_Colocalization
cso30:i:CC_MitochondrialIntermembraneSpace
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c141 : 1
stoichiometry:c142 : 1
stoichiometry:c143 : 1
m79*m68199*0.1
nodelay
--
0
PMID: 18549796 NS3/4A, colocalizes with MAVS at the mitochondria and specifically targets MAVS as a means to inhibit IFN production.
p51
p51
cso30:i:ME_ProteinCleavage
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c144 : 1
stoichiometry:c146 : 1
stoichiometry:c145 : 1
m68199*m79*0.1
nodelay
--
0
PMID: 18549796, 18272355 NS3/4A contains serine-protease activity that proteolytically cleaves MAVS at the cysteine-508 resulting in the loss of MAVS mitochondrial localization.
p52
p52
cso30:i:ME_ProteinCleavage
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c147 : 1
stoichiometry:c149 : 1
stoichiometry:c148 : 1
m18998*m79*0.1
nodelay
--
0
PMID: 18549796 Interestingly, NS3/4A also cleaves TRIF, the essential adaptor of TLR3-signaling, thereby extending the IFN inhibitory properties of HCV to TLR-mediated responses.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c150 : 1
stoichiometry:c151 : 1
stoichiometry:c152 : 1
m81*m41844*0.1
nodelay
--
0
PMID: 18549796, 17079289 NS1 was found to complex with RIG-I and associate with MAVS at the mitochondria, thereby disrupting downstream activation of IRF-3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c153 : 1
stoichiometry:c154 : 1
stoichiometry:c155 : 1
m81*m68199*0.1
nodelay
--
0
PMID: 18549796, 17079289 NS1 was found to complex with RIG-I and associate with MAVS at the mitochondria, thereby disrupting downstream activation of IRF-3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c158 : 1
stoichiometry:c159 : 1
m14*0.1
nodelay
--
0
PMID: 18549796, 16125763 Upon viral challenge, the MAVS CARD associates with the CARDs of RIG-I or MDA-5. PMID: 18549796 TRIM25, functions as an E3 ubiquitin ligase of RIG-I. The SPRY domain of TRIM25 delivers a lysine 63-linked ubiquitin moiety to the N-terminal CARDs of RIG-I, which strengthens interactions with MAVS and enhances downstream signaling to IFN-¦Â. PMID: 18549796 NLRX1 was found to interact with MAVS and block RIG-I-MAVS interactions and signaling after Sendai virus infection.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c163 : 1
stoichiometry:c161 : 1
m38*0.1
nodelay
--
0
PMID: 18549796 Because it is known that both NF-¦ÊB and IRF3 and IRF7 are required for the assembly of an enhancesome complex required for the induction of IFN-¦Â and IFN-¦Á promoters, the essential role of MAVS in the activation of both of these transcription factors further emphasizes the importance of this mitochondrial adaptor protein in type-1 interferon signaling.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c162 : 1
stoichiometry:c160 : 1
m41*0.1
nodelay
--
0
PMID: 18549796 Because it is known that both NF-¦ÊB and IRF3 and IRF7 are required for the assembly of an enhancesome complex required for the induction of IFN-¦Â and IFN-¦Á promoters, the essential role of MAVS in the activation of both of these transcription factors further emphasizes the importance of this mitochondrial adaptor protein in type-1 interferon signaling.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c13 : 1
stoichiometry:c12 : 1
m6*0.1
nodelay
--
0
PMID: 18549796 The ligands for RIG-I and MDA-5 are viral ¡Ènonself¡É nucleic acids, and like TLR signaling, a classical ligand-receptor-adaptor model of PRR signaling has been proposed for RLH-mediated signaling, culminating in the induction of antiviral type-1 interferon cytokines, such as IFN-¦Â and IFN-¦Á.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c15 : 1
stoichiometry:c16 : 1
stoichiometry:c19 : 1
m68199*m5*0.1
nodelay
--
0
PMID: 18549796, 16125763 Upon viral challenge, the MAVS CARD associates with the CARDs of RIG-I or MDA-5.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c18 : 1
stoichiometry:c17 : 1
stoichiometry:c132 : 1
stoichiometry:c20 : 1
m68199*m63*0.1
nodelay
--
0
PMID: 18549796, 16125763 Upon viral challenge, the MAVS CARD associates with the CARDs of RIG-I or MDA-5. PMID: 18549796 TRIM25, functions as an E3 ubiquitin ligase of RIG-I. The SPRY domain of TRIM25 delivers a lysine 63-linked ubiquitin moiety to the N-terminal CARDs of RIG-I, which strengthens interactions with MAVS and enhances downstream signaling to IFN-¦Â. PMID: 18549796 NLRX1 was found to interact with MAVS and block RIG-I-MAVS interactions and signaling after Sendai virus infection.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c21 : 1
stoichiometry:c22 : 1
stoichiometry:c23 : 1
m14*m1872*0.1
nodelay
--
0
PMID: 18549796, 18272355 The MAVS proline-rich domain contains a TRAF3-binding site required for association with TRAF3 and essential for MAVS-mediated activation of type-1 interferon, but not NF-¦ÊB.
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--